Last updated: August 20, 2026
Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met both its recurrence free survival and distant metastasis free survival endpoints in resected melanoma, without disclosing effect sizes. Amylyx launched a $350 million stock offering one day after its avexitide Phase 3 win.
This page covers the INTerpath-001 topline result and how it compares with the Phase 2b data, the Amylyx offering, President Trump’s formal nomination of Dr. Heidi Overton to lead the FDA, the D.C. Circuit’s ruling in Teva’s Medicare price negotiation case, and the Tolerance Bio licensing deal, all from August 19, 2026.
What did the INTerpath-001 Phase 3 trial show?
INTerpath-001 met its primary endpoint of recurrence free survival and its key secondary endpoint of distant metastasis free survival at a prespecified interim analysis, in 1,137 patients with completely resected stage IIB to IV melanoma. Merck and Moderna called the improvements statistically significant and clinically meaningful but released no numbers.
The trial, also known as V940-001 (NCT05933577), is a randomized, double blind, placebo and active comparator controlled global Phase 3 study. Patients who had their cutaneous melanoma completely removed by surgery and had received no prior treatment were randomized two to one to intismeran autogene plus pembrolizumab (Keytruda) or to pembrolizumab alone. Intismeran autogene, previously known as V940 and mRNA-4157, is an individualized neoantigen therapy: each patient’s tumor is sequenced, and a synthetic messenger RNA is manufactured encoding up to 34 neoantigens specific to that patient’s mutational signature. The companies reported no new safety signals, and the study continues for overall survival, safety, and quality of life.
| INTerpath-001 design | Detail |
|---|---|
| Population | Completely resected stage IIB to IV cutaneous melanoma, treatment naive |
| Enrollment | 1,137 patients, randomized 2:1 |
| Arms | Intismeran autogene 1 mg every three weeks (up to nine doses) plus pembrolizumab 400 mg every six weeks (up to nine cycles, about one year) vs pembrolizumab alone |
| Primary endpoint | Recurrence free survival: MET at prespecified interim analysis |
| Key secondary endpoint | Distant metastasis free survival: MET |
| Effect sizes | Not disclosed; data to be presented at an upcoming international medical meeting |
| Safety | No new safety signals; consistent with prior studies of the combination |
| Still to come | Overall survival (trial continuing), full data presentation, regulatory filings |
Source: Merck and Moderna joint press release, August 19, 2026.
How does the Phase 3 result compare with the earlier KEYNOTE-942 data?
The Phase 2b KEYNOTE-942 trial reported a hazard ratio of 0.510 for recurrence free survival and 0.411 for distant metastasis free survival at five years in 157 patients. The Phase 3 enrolled a broader population more than seven times that size, and analysts expect some compression of the effect.
| Measure | Phase 2b KEYNOTE-942 (5 year follow up, Jan 2026) | Phase 3 INTerpath-001 (Aug 2026 topline) |
|---|---|---|
| Patients | 157, high risk stage III/IV, resected | 1,137, stage IIB to IV, resected |
| Recurrence free survival | HR 0.510 (95% CI, 0.294 to 0.887); 49% reduction in risk of recurrence or death | Met; magnitude not disclosed |
| Distant metastasis free survival | HR 0.411 (95% CI, 0.200 to 0.843); 59% reduction in risk | Met; magnitude not disclosed |
| Comparator | Pembrolizumab alone | Pembrolizumab alone |
Two cautions apply when reading across the columns. First, KEYNOTE-942 enrolled stage III and IV patients, while the Phase 3 reaches down into stage IIB, a lower risk population where fewer events accrue and treatment effects are typically harder to demonstrate. Second, a Phase 2b hazard ratio with a confidence interval running from 0.294 to 0.887 is an imprecise estimate by construction. Fierce Biotech reported that Citi analysts framed a Phase 3 hazard ratio of 0.72 or better as a positive result and 0.65 or better as a clear win, and that Jefferies expected something in the 0.5 to 0.8 range. Until the companies present the data at a medical meeting, the honest description of INTerpath-001 is a statistical win of unknown size.
What happens next for intismeran autogene?
Merck and Moderna said they will present the data at an upcoming international medical meeting and will engage regulators on filing submissions. No filing timeline was given. The FDA declined an accelerated approval bid based on the Phase 2b data in 2024, according to Fierce Biotech.
That 2024 history matters for handicapping the filing. The agency has already told these companies once that the Phase 2b data were not enough, which is why INTerpath-001 exists at its current size. A Phase 3 that meets both endpoints in a conventional adjuvant design is the package the agency asked for, and melanoma adjuvant therapy is a well trodden regulatory path. The manufacturing question is the novel part: each course of intismeran autogene is a bespoke product made for one patient, and the review will cover a manufacturing process as much as a molecule. Beyond melanoma, the companies have nine Phase 2 and Phase 3 trials running across non small cell lung cancer, bladder cancer, and renal cell carcinoma, with additional work in pancreatic and gastric cancer. The melanoma result is the proof of concept for all of it.
Why did Amylyx launch a $350 million offering one day after its Phase 3 win?
Amylyx Pharmaceuticals announced a proposed underwritten public offering of $350.0 million of common stock on August 18, one day after reporting that avexitide cut hypoglycemic events by 55 percent in the Phase 3 LUCIDITY trial. Underwriters hold a 30 day option for up to $52.5 million more.
The company said proceeds will fund pre commercial activities for avexitide, including manufacturing capacity, along with research and development and working capital. Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital are joint bookrunners, and the shares come off an S-3ASR shelf that went effective March 3, 2026. As of Wednesday night the offering had been announced but not priced.
| Amylyx offering terms | Detail |
|---|---|
| Announced | August 18, 2026, one day after LUCIDITY topline |
| Base size | $350.0 million of common stock, underwritten |
| Overallotment | 30 day underwriters option, up to $52.5 million additional |
| Use of proceeds | Avexitide pre commercial work including manufacturing capacity, R&D, working capital |
| Bookrunners | Leerink Partners, Morgan Stanley, Guggenheim Securities, LifeSci Capital |
| Status | Proposed; not priced as of August 19 |
The sequencing is the story. Silence Therapeutics closed an upsized $201.3 million offering within days of its divesiran Phase 2 win earlier this month, and Amylyx has now followed the same playbook at a larger scale: report the readout, let the stock reprice, and sell equity into the pop before the next binary appears. With an NDA planned by year end under Breakthrough Therapy designation and a launch to build in a diagnosis limited population, raising at strength is the rational move, and it is exactly the behavior our running binary ledger is designed to track.
Who did President Trump nominate to lead the FDA?
President Trump formally announced on Wednesday, August 19, via a post on Truth Social, that he is nominating Dr. Heidi Overton as FDA commissioner. The move converts Tuesday’s sourced reports into an official nomination. Senate confirmation is required, and no hearing date has been set.
Overton is a physician and deputy director of the White House Domestic Policy Council, with a record in drug pricing negotiations, the childhood vaccine schedule overhaul, and the food pyramid redesign rather than in drug review. The FDA has operated under acting leadership since Marty Makary left the agency earlier this year. Nothing about Wednesday’s announcement changes the decision calendar: every pending action date through the fourth quarter, from Capricor’s deramiocel file to Scholar Rock’s September 30 date, rusfertide this quarter, Summit’s November 14 ivonescimab decision, and Vertex’s November 30 povetacicept date, is decided by the acting structure. The confirmation hearing, once scheduled, is the first place the next FDA’s views on post hoc analyses and manufacturing findings could go on the record.
What did the appeals court decide in Teva’s Medicare price negotiation case?
The D.C. Circuit rejected Teva’s two central challenges to the Medicare drug price negotiation program on August 18 but revived one narrower claim, sending Teva’s challenge to CMS’s bona fide marketing standard back to the district court for a first ruling on the merits.
The unanimous panel (Judges Henderson, Childs, and Pan, opinion by Judge Childs, in Teva Pharmaceuticals USA v. Kennedy) held that CMS may treat Austedo and Austedo XR as a single negotiation eligible drug because they share an active moiety and a manufacturer, and that the program does not violate due process because participation in Medicare is voluntary and confers no protected property interest. The revived claim is narrower but not trivial: whether CMS exceeded its statutory authority when it required that a competing generic be bona fide marketed before a branded drug escapes negotiation. The court drew a line worth remembering, holding that the statute’s bar on judicial review covers CMS’s drug specific determinations but not the generally applicable legal standards behind them. That distinction is now the roadmap for every manufacturer looking for a reviewable question inside the IRA.
| Teva claim | Outcome at the D.C. Circuit |
|---|---|
| Austedo and Austedo XR grouped as one drug | Rejected; CMS interpretation upheld |
| Due process violation | Rejected; no protected property interest |
| Bona fide marketing standard exceeds CMS authority | Revived; ripe for review, remanded to district court |
What did Tolerance Bio license from NeoImmuneTech?
Tolerance Bio licensed efineptakin alfa, a clinical stage long acting interleukin 7 fusion protein, from Korea’s NeoImmuneTech for the Americas and Europe. The consideration is equity of undisclosed size plus up to $260 million in development and sales milestones plus tiered royalties, with essentially no cash upfront.
Efineptakin alfa (NT-I7) stimulates thymic function and T cell differentiation, proliferation, and survival, and has been dosed in more than 800 subjects across 15 clinical studies, mostly in oncology settings. Tolerance Bio plans to take it into Phase 2 for enhancement of thymic function, starting in HIV immunological non response as a model of accelerated immune aging. The deal structure is the notable part for dealwatchers: measured in cash, the upfront rounds to zero, which places it at the far end of the contingent consideration curve this week, past Sandoz and Henlius’s almost entirely milestone based biosimilar framework, LEO’s cash heavy purchase of a filed asset, and BioMarin’s majority cash purchase of Alesta.
Where does the binary ledger stand after Wednesday?
The running ledger of who holds binary risk, and what they were paid to hold it, added two entries on Wednesday: Amylyx joined the column of winners selling equity into the pop, and Tolerance Bio’s license joined the column of contingent consideration written. The full tally comes Friday.
| Ledger column | This week’s entries through Wednesday |
|---|---|
| 1. Deferrals granted by regulators | Capricor deramiocel (FDA willing to extend the August 22 date on receipt of a BLA amendment, per the company; no FDA notice yet) |
| 2. Contingent payments in litigation | Celgene CVR suit revived by the Second Circuit August 13 |
| 3. Winners selling equity into the pop | Silence Therapeutics $201.3 million (closed August 14); Amylyx $350.0 million proposed offering plus $52.5 million option (August 18) |
| 4. Royalties sold ahead of decisions | Zealand’s rusfertide royalty to Royalty Pharma for $100 million |
| 5. Creation vehicles absorbing binaries | Fibrx (Skye plus Redx, about $125 million); Slate/Fulcrum ($245 million PIPE) |
| 6. Contingent consideration written | Lilly/OmniAb; BioMarin/Alesta (up to $490 million, 56 percent cash); LEO/Tanabe dersimelagon (up to $435 million upfront and near term); Sandoz/Henlius (up to $322 million); Tolerance Bio/NeoImmuneTech (equity plus up to $260 million milestones, cash near zero) |
| 7. Binaries returned to sender | J&J returned prizloncabtagene autoleucel to AbelZeta |
Merck and Moderna belong on this page as the counterexample, alongside AstraZeneca’s portfolio: the biggest binary to resolve this week was held inside two large balance sheets, so nobody sold equity, nobody wrote a CVR, and nobody had to disclose a number before a medical congress. Holding your own binaries is a privilege of scale.
Frequently asked questions
What is intismeran autogene?
Intismeran autogene, formerly V940 and mRNA-4157, is an individualized neoantigen therapy from Merck and Moderna. Each patient’s tumor is sequenced and a synthetic mRNA is made encoding up to 34 neoantigens unique to that tumor, training T cells to attack residual cancer.
Did the INTerpath-001 trial succeed?
Yes. Merck and Moderna said the trial met its primary endpoint of recurrence free survival and its key secondary endpoint of distant metastasis free survival at a prespecified interim analysis, with statistically significant and clinically meaningful improvements over pembrolizumab alone.
What hazard ratio did INTerpath-001 show?
The companies did not disclose effect sizes. The data will be presented at an upcoming international medical meeting. Fierce Biotech reported analyst framing in which a hazard ratio of 0.72 or better would be positive and 0.65 or better a clear win.
Is intismeran autogene approved anywhere?
No. The FDA declined an accelerated approval bid based on Phase 2b data in 2024, per Fierce Biotech. The companies say they will now engage regulators on filings based on the Phase 3 result.
Who makes the mRNA melanoma vaccine?
Moderna manufactures intismeran autogene, and Merck co develops and co commercializes it under a partnership dating to 2016; Merck sells pembrolizumab (Keytruda), the checkpoint inhibitor it pairs with.
Why is a cancer vaccine given with Keytruda?
The vaccine primes T cells against tumor specific neoantigens, while pembrolizumab blocks the PD-1 checkpoint that tumors use to switch those T cells off. The combination attacks residual disease through two complementary mechanisms after surgery.
How big was the Amylyx stock offering?
Amylyx announced a proposed underwritten public offering of $350.0 million of common stock on August 18, 2026, with a 30 day underwriters option for up to $52.5 million more. It had not priced as of August 19.
What will Amylyx use the offering proceeds for?
The company said proceeds will fund pre commercial activities for avexitide, including manufacturing capacity, plus research and development and working capital. Amylyx plans an NDA for avexitide in post bariatric hypoglycemia by the end of 2026.
What did avexitide show in Phase 3?
In the 78 patient LUCIDITY trial, avexitide reduced the composite of Level 2 and Level 3 hypoglycemic events by 55 percent versus placebo (p=0.000003) in post bariatric hypoglycemia and met all key secondary endpoints.
Is Heidi Overton the FDA commissioner now?
No. President Trump announced her nomination on August 19, 2026. She must be confirmed by the Senate, and no hearing date has been set. The FDA continues under acting leadership, which decides every pending application in the meantime.
What did Teva win at the D.C. Circuit?
Teva won review of one claim: whether CMS exceeded its authority with the bona fide marketing requirement for generics. The court rejected Teva’s challenges to grouping Austedo and Austedo XR as one drug and its due process claim.
Does the Teva ruling threaten Medicare drug price negotiation?
Not broadly. The core program survived intact, as it has in every appellate challenge so far. The remanded claim affects when a branded drug exits negotiation after generic entry, a meaningful but narrow question.
What is efineptakin alfa?
Efineptakin alfa (NT-I7) is a long acting interleukin 7 fusion protein developed by NeoImmuneTech that stimulates thymic function and T cell production. Tolerance Bio licensed Americas and Europe rights on August 19 to develop it for thymic function enhancement, starting in HIV immunological non response.
What is the binary ledger?
It is our running framework for the week of August 17: a count of who holds high stakes binary events (FDA decisions, readouts, contingent payments) and what they were paid, across seven columns from regulatory deferrals to assets returned to their originators. The full tally publishes Friday.
Sources
Primary sources (August 18 to 19, 2026): Merck and Moderna joint press release on INTerpath-001 (August 19); Moderna press release on KEYNOTE-942 five year data (January 20, 2026); Amylyx Pharmaceuticals offering announcement (Business Wire, August 18); U.S. Court of Appeals for the D.C. Circuit opinion in Teva Pharmaceuticals USA v. Kennedy, No. 25-5425 (August 18); Tolerance Bio and NeoImmuneTech joint release (August 19); Amylyx LUCIDITY topline release (August 18); Capricor Therapeutics press releases (March 10 and August 13).
Trade press and market coverage (attributed where used): Fierce Biotech on INTerpath-001 analyst expectations and the 2024 accelerated approval decision (August 19); Fierce Pharma on the Teva ruling (August 19); CBS News and other outlets on the Overton nomination announcement (August 19); STAT on gene editing experts and HuidaGene (August 19); Fierce Biotech on the Tolerance Bio deal (August 19).
Related coverage
- Trump is expected to nominate Heidi Overton to lead the FDA, while Amylyx cut hypoglycemic events 55% in Phase 3
- EyePoint’s Duravyu missed its wet AMD Phase 3 while AstraZeneca ended one lung cancer trial and won two
- Capricor is amending its deramiocel BLA ahead of the August 22 PDUFA
- PTC and Lilly just bought Sangamo for parts
- Retatrutide vs CagriSema: why 2026 is the year of the triple agonist
